Company Analysis
Sign in

Xenon Pharmaceuticals Inc. (XENE)

Nasdaq: XENE · Pharmaceutical Preparations · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.6
◀ Past 4.3● Present 5.1▶ Future 4.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$7.5M
Net income-$346M-47.6%
Earnings per share$-4.36-44.9%
Operating cash flow-$279M-53.9%
Cash$199M+39.6%
Debtn/a
Shareholders’ equity$582M-22.9%
Shares, diluted79.3M+1.7%
Return on equity-59.5%
The recordfrom its filings
Filings in 202683
Newest filingNov 9 · S-8
Annual reportFeb 26, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$22.0M
Insider buys, 12 months$1.7M
Patents granted110
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $0.00Net income -$429MCash from operations -$356Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 9, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton XENE · research, not advice